Video

Manpreet K. Singh, MD: The Challenge of Treating ADHD With Comorbidities

Author(s):

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

Treating ADHD can be challenging, largely because the disease often comes with other psychiatric comorbidities.

It is not uncommon for patients with ADHD to also have major depressive disorder, generalized anxiety disorder, or a mood or personality disorder as well.

However, the challenge is in treatments and dosing and treating some of the symptoms between 2 psychiatric disorders that do not necessarily overlap.

Does treating the ADHD first make sense, should you treat all conditions simultaneously, or should you tackle the comorbidities before the ADHD?

In addition, should patients be screened for other psychiatric disorders when they are initially diagnosed with ADHD?

In an interview with HCPLive® Manpreet K. Singh, MD, Assistant Professor of Psychiatry and Behavioral Sciences, Stanford University, discussed what the optimal treatment plan is for patients with ADHD and other comorbidities.

Singh recently presented on this topic during the American Professional Society of ADHD and Related Disorders (2023) Annual Meeting in Orlando on the intersection between ADHD and mood disorders, specifically bipolar disorder.

She said largely the attention issues is what may lead to some of the other psychiatric symptoms.

“I consider attention problems the gateway symptoms,” Singh said. “They tend to present very early when the brain is still developing and undergoing to key plasticity to be able to regulate emotions.”

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Carla Nester, MD | Credit: HCPLive
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
© 2024 MJH Life Sciences

All rights reserved.